High systemic inflammation response index and increased cardiovascular risk and mortality in MASLD: A prospective cohort study [0.03%]
系统炎症反应指数升高与代谢相关脂肪性肝病患者心血管风险和死亡率增加有关：前瞻性队列研究
Haixiang Zheng,Kuangyi Wu,Hong Zheng et al.
Haixiang Zheng et al.
Background & aims: The correlation between systemic inflammation response index (SIRI) and both cardiovascular disease (CVD, including myocardial infarction and total stroke) and mortality in individuals with metabolic dy...
Stage-dependent effects of systemic ASBT inhibition in a cholestasis-induced cholemic nephropathy mouse model [0.03%]
基于胆汁淤积性胆尿症小鼠模型的ASBT抑制剂的抗肾毒性作用及机制研究
Ahmed Ghallab,Maiju Myllys,Daniela González et al.
Ahmed Ghallab et al.
Background & aims: Cholemic nephropathy (CN) is a severe complication of liver diseases associated with cholestasis and represents an unmet medical need. Recently, we identified the molecular mechanism of CN and showed th...
PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study [0.03%]
程序性死亡配体1与慢性肝病患者细菌感染风险的关联：一项国际多队列研究
Adrià Juanola,Gabriel Mezzano,Elisa Pose et al.
Adrià Juanola et al.
Background & aims: Impaired phagocytic capacity due to activation of the PD-1/PD-L1 pathway has been implicated in the development of bacterial infections in patients with cirrhosis. Soluble PD-L1 (sPD-L1) is easily measu...
Artificial intelligence predicts outcome-related molecular profiles and vascular invasion in hepatocellular carcinoma [0.03%]
人工智能预测肝细胞癌的结局相关分子特征和血管浸润
Tobias Paul Seraphin,Agavni Mesropian,Laura Žigutytė et al.
Tobias Paul Seraphin et al.
Background & aims: Advances in digital pathology and artificial intelligence (AI) are driving progress toward personalized clinical management. In hepatocellular carcinoma (HCC), AI-based models using digitized H&E slides...
Development of a CRE/CREB-driven HBx responsive HBV cell culture reporter system for antiviral drug evaluation [0.03%]
开发用于抗病毒药物评价的HBV细胞培养报告系统中的CRE/CREB驱动型HBx响应单元
Muhammad Atif Zahoor,Nahla FadlElMawla,Adrian Kuipery et al.
Muhammad Atif Zahoor et al.
Background & aims: Chronic HBV infection is a leading cause of liver disease and cancer. Current therapies fail to eliminate covalently closed circular DNA (cccDNA), underscoring the need for novel strategies. We aimed to...
Evaluating large language models' performance in answering common questions on drug-induced liver injury [0.03%]
评估大型语言模型在药物性肝损伤常见问题回答中的表现
Yinuo Dong,Zili Zhang,Yang Zhi et al.
Yinuo Dong et al.
Background & aims: Drug-induced liver injury (DILI) is a complex condition often linked to medication behaviors, with patient education having a crucial role in optimizing outcomes. Large language models (LLMs) could serv...
Improved survival in patients with refractory variceal bleeding treated with esophageal stents: A multicenter cohort study [0.03%]
食管支架治疗难治性静脉曲张出血患者的效果优于其他方法：一项多中心队列研究
Delphine Weil,Morgane Clément,Charlotte Bouzbib et al.
Delphine Weil et al.
Background & aims: Tamponade is a bridge therapy for refractory variceal bleeding. This study compared esophageal stents (ESs) and balloon tamponade (BT) in terms of early bleeding control and mortality. ...
A retrospective evaluation of preemptive liver transplantation for bile duct dysplasia in primary sclerosing cholangitis: Balancing risks and benefits [0.03%]
原发性硬化性胆管炎胆管发育不良肝移植的回顾性分析：评估预防性肝移植的风险和获益
Sigurd Breder,Christina Villard,Emma Eide et al.
Sigurd Breder et al.
Background & aims: Liver transplantation (LT) to prevent cholangiocarcinoma (CCA) in individuals with primary sclerosing cholangitis (PSC) and bile duct dysplasia was introduced in Norway and Sweden in the early 2000s. We...
R-spondin 2 suppresses hepatic steatosis via activation of AMPK-ACC signaling [0.03%]
R-spondin 2通过激活AMPK-ACC信号通路抑制肝脂肪变性
Ravi Varma Aithabathula,Bhupesh Singla,Ishita Kathuria et al.
Ravi Varma Aithabathula et al.
Background & aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) primarily results from dysregulated lipid metabolism in hepatocytes. However, the mechanisms governing hepatic lipid metabolism remain in...
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study [0.03%]
仑伐替尼对比索拉非尼用于阿特珠单抗联合贝伐珠单抗治疗后的肝细胞癌二线治疗：LEVIATHAN研究
Pasquale Lombardi,Jung Sun Kim,Giulia F Manfredi et al.
Pasquale Lombardi et al.
Background & aims: Atezolizumab plus bevacizumab (A+B) is a standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). However, optimal sequencing strategies after A+B failure remain undefined. ...